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1  |  INTRODUCTION
Cystic Fibrosis (CF) is an autosomal recessive genetic dis-
ease that affects over 30,000 people in the United States 
and results from mutations in the cystic fibrosis trans-
membrane conductance regulator (CFTR)  gene that 
disrupt the CFTR synthesis, folding, or function. The 
CFTR protein is a well- characterized cAMP- regulated 
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Abstract
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the CF trans-
membrane conductance regulator (CFTR) gene. The F508del and G542X are the 
most common mutations found in US patients, accounting for 86.4% and 4.6% 
of all mutations, respectively. The F508del causes deletion of the phenylalanine 
residue at position 508 and is associated with impaired CFTR protein folding. The 
G542X is a nonsense mutation that introduces a stop codon into the mRNA, thus 
preventing normal CFTR protein synthesis. Here, we describe the generation of 
CFTRF508del/F508del and CFTRG542X/G542X lambs using CRISPR/Cas9 and somatic 
cell nuclear transfer (SCNT). First, we introduced either F508del or G542X muta-
tions into sheep fetal fibroblasts that were subsequently used as nuclear donors 
for SCNT. The newborn CF lambs develop pathology similar to CFTR−/− sheep 
and CF patients. Moreover, tracheal epithelial cells from the CFTRF508del/F508del 
lambs responded to a human CFTR (hCFTR) potentiator and correctors, and 
those from CFTRG542X/G542X lambs showed modest restoration of CFTR function 
following inhibition of nonsense- mediated decay (NMD) and aminoglycoside 
antibiotic treatments. Thus, the phenotype and electrophysiology of these novel 
models represent an important advance for testing new CF therapeutics and gene 
therapy to improve the health of patients with this life- limiting disorder.
K E Y W O R D S
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ATP- binding cassette (ABC) transporter responsible for 
regulating anion transport, primarily chloride ions.1 The 
CFTR protein is expressed in epithelial cells of multiple 
organs such as the airways, pancreas, intestine, gallblad-
der, and male genital ducts. Important features of human 
CF pathology are early damage to the pancreas, which ini-
tiates when pancreatic acini become functional in utero, 
intestinal obstruction, and persistent lung inflammation 
associated with infection that causes tissue damage and 
fibrosis (Reviewed in2). One of the impediments in ad-
vancing the understanding of disease mechanisms is the 
limited ability of most CF animal models to recapitulate 
some aspects of the disease phenotype observed in hu-
mans (reviewed in3,4). Of particular importance is the eti-
ology of early lung pathology, which is likely triggered by 
functional inactivation of CFTR protein early in life.5
There are over 2000 predicted CFTR mutations that are 
divided into six classes, depending on how they affect the 
protein.6 The F508del mutation is the most frequent in 
human patients in the United States, followed by G542X. 
The F508del is identified in 84.7% of patients on at least 
one allele, whereas the G542X is present at a frequency 
of 4.6%.7 The F508del mutation is characterized by loss of 
a phenylalanine residue at the position 508 (F508) of the 
CFTR protein and is classified as a Class II alteration since 
it causes defective processing/trafficking. F508del protein 
is misfolded and retained in the endoplasmic reticulum 
(ER) where it is further degraded by proteolytic cleavage.8 
As the most common human CFTR mutation, the F508del 
CF sheep was considered necessary as a valid ovine model 
for evaluating lung disease progression in sheep and the 
development of future therapeutic treatments. Though 
substantial progress has been made with small mole-
cule approaches to correct this mutant phenotype9,10 (re-
viewed in11), some patients are poorly responsive to these 
treatments.
Although effective treatments are now available for 
CF patients with at least one F508del allele, there is still a 
great need for therapeutics that target CFTR nonsense mu-
tations (e.g., G542X). These nonsense mutations are Class 
I alterations, which lack full length of the CFTR protein 
production and are often targets for nonsense- mediated 
decay (NMD) of RNA. Nearly 10% of CF patients carry 
Class I mutations, the most common being G542X, a G to 
T substitution in the first nucleotide of the glycine codon 
(GGA) at position 542 of the protein. This mutation pro-
duces a premature termination codon (PTC), which trig-
gers the surveillance pathway and causes mRNA NMD, 
leading to the lack of CFTR protein production.12
To the best of our knowledge, no large animal model 
carrying the G542X mutation has been produced to 
study in- depth the nonsense mutations that affect CF pa-
tients. Therefore, to better elucidate the pathophysiologic 
effects of the F508del and G542X mutations, we pro-
duced CFTRF508del/F508del and CFTRG542X/G542X sheep using 
CRISPR/Cas9 ribonucleoprotein (RNP) along with donor 
single- stranded oligonucleotide (ssODN) to introduce ei-
ther the F508del or G542X mutations in the CFTR gene 
of sheep fetal fibroblasts followed by somatic cell nuclear 
transfer (SCNT). Here, our goal was to investigate whether 
F508del and G542X CF sheep models exhibit the same 
phenotypes as were observed in the CFTR−/− sheep we 
generated previously.5 Also it was important to establish 
the presence of residual CFTR channel activity in F508del 
CF sheep. We evaluated the effect of CFTR correctors 
(VX- 661 (Tezacaftor),13 VX- 809 (Lumacaftor),14 and VX- 
445 (Elexacaftor)15) and potentiator (VX- 770 (Ivacaftor)16) 
on the restoration of the CFTR channel function in the 
F508del CF sheep tracheal epithelial (STE) cells by elec-
trophysiology. We also measured the impact of amino-
glycoside antibiotics (gentamicin (G418))17 and the NMD 
inhibitor (SMG1- i (2- chloro- N,N- diethyl- 5- ((4- (2- (4- (3- m
ethylureido)phenyl)pyridin- 4- yl)pyrimidin- 2- yl)amino)
benzenesulfonamide))18 in G542X CF STE cells. These 
novel F508del and G542X CF sheep models could become 
a critical platform for studying the effects of CFTR muta-
tions during fetal development, the mechanisms of onset 
of lung inflammation, and also provide support for new 
therapeutic strategies including prenatal therapy toward a 
genetic cure of the disease.
2  |  METHODS
2.1 | Animals
Domestic Romney sheep (Ovis aries) were used in this 
study for isolation of sheep fetal fibroblasts (SFFs), and 
Suffolk and Rambouillet ewes were used as recipients 
for embryo transfers. All animal studies were approved 
and monitored by the Institutional Animal Care and Use 
Committee (IACUC) at Utah State University (IACUC pro-
tocol #10089) and conformed to the National Institute of 
Health guidelines. CFTRF508del/F508del and CFTRG542X/G542X 
cloned lambs were generated by SCNT using genetically 
modified SFFs as nucleus donor cells.
2.2 | Sheep fetal fibroblasts
Sheep fetal fibroblasts were isolated from male day 45 
Romney fetus as previously described and cultured in 
Dulbecco's modified Eagle's medium ((DMEM) high glu-
cose; HyClone) supplemented with 15% fetal bovine serum 
(FBS; HyClone) and 100 U/mL penicillin– streptomycin (Life 
Technologies) at 38.5℃ in an atmosphere of 5% CO2 in air.19
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2.3 | Design of guide RNAs/Cas9 and 
single- strand oligonucleotides
Based on the sequence results for exons 11 and 12 of the 
ovine CFTR gene, we designed gRNAs targeting the re-
gions flanking the phenylalanine (F508) site in exon 
11 and the Glycine (G542) site in exon 12 using the 
Benchling software (https://bench ling.com/academic) 
(Figure  1). The gRNA_1 targets the F508  site with the 
intended “CTT” deletion located within the first and 
third nucleotide at 3’ end. The gRNA_2 targets the G542 
DNA locus with the target nucleotide (Guanine) located 
within five positions upstream to the CRISPR/Cas9 
double- strand break site. The gRNAs were synthesized 
by Synthego with chemical modifications (2’- O- methyl 
3’- phosphorothioate modifications in the first and last 
three nucleotides). The TrueCut™ Cas9  V2 protein was 
purchased from Thermo Fisher Scientific. To introduce 
the point mutations, we also designed ssODNs carrying 
either the G542X or F508del mutations as gene- editing 
donor oligos with 50  bp homologous arms flanking the 
mutation sites. The ssODN_1 (5’- T*G*CTCTCAGTATTC
CTGGATCATGCCTGGAACCATTAAAGATAACATCA
TTGGTGTTTCCTATGATGAATATAGATATAGGAGTG
TCATCAAAGCATG*C*C- 3’) carried the F508del muta-
tion (a deletion of three consecutive nucleotides, “CTT”) 
and the ssODN_2 (5’- T*T*TGATAATAGGACATCTCC
AAGTTTTCAGAGAAAGACAACATAGTTCTTTGAGA
AGGTGGAATCACATTGAGTGGAGGTCAGCGAGCA
AGAATTTCTT*T*A- 3’) contained the G542X mutation 
(a “G” nucleotide was replaced with a “T” (bold) leading 
to the generation of a stop codon, “TGA”). Both ssODNs 
were synthesized by Integrated DNA Technologies (IDT) 
containing two phosphorothioate modifications (*) at 
both 5’ and 3’ ends.
2.4 | Transfection and mutation 
efficiency detection
Nucleofection was performed using an Amaxa 
Nucleofector System (Program EH- 100, Lonza). Prior 
to transfection, 3  µl of 100  µM gRNA was  incubated 
with 2  µl of 5  µg/µl Cas9 protein for 10  min at room 
temperature to form a ribonucleoprotein (RNP) com-
plex. The RNP was then incubated with 2 µl of 200 µM 
ssODN for 5 min and transfected into 2 × 105 SFFs, in 
Passage 3, in a 100  µl nucleocuvette system. Two days 
F I G U R E  1  Generation of CFTRF508del/F508del and CFTRG542X/G542X sheep fetal fibroblast cells and lambs. (A) Schematic diagram of 
CRISPR/Cas9 target sites in exon 11 and 12 for introduction of the F508del and G542X mutations using the ssODN_1 and 2, respectively. 
The blue arrows represent the primers used to amplify the exon 11 and 12. (B) Representative sequence analysis for cell colonies and lambs 
containing F508del, similar to the CF patients, the “CTT” nucleotides are deleted between the codons ATC and TTT. Sequencing results 
indicate that four isolated cell colonies and two cloned lambs contained homozygous F508del mutations. (C) Representative sequence 
analysis for cell colonies and lambs containing G542X mutation. Similar to the G542X CF patients, Glycine- encoded codon “GGA” is 
mutated with a single nucleotide replacement, “G” to “T,” leading to the generation of stop codon, “TGA.” Sequencing results demonstrate 
that all nine SFF cell colonies and three cloned fetus/lambs present the same homozygous G542X mutation. The arrow represents the point 
mutation site and the codon sequences are framed
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post- transfection, cells were harvested for genomic 
DNA isolation using the DNeasy Blood & Tissue kit 
(Cat. 69504, Qiagen) following the manufacturer's 
protocol. Each of the targeted genomic loci was PCR 
amplified by Phusion High- fidelity DNA polymerase 
(Thermo Fisher Scientific) using the genomic DNA 
isolated from transfected SFFs as templates and the 
primers (F: 5’- TGAACTCAGCACCCCATCTCTG- 3’; R: 
5’- TGCAGGCTTCTTATAGCAGGGG- 3’) for F508 locus, 
and the primers (F: 5’- GCTGAGATGT GGTGTTCACA- 3’; 
R: 5’- GCATCTTCTCTTCC CTGTGC- 3’) for G542 locus. 
Both PCR products were analyzed by Sanger sequencing 
before cell colony isolation.
2.5 | Isolation of F508del and G542X 
cell colonies
Three days after gRNA/Cas9/ssODN transfection, cells 
were subjected to single- cell colony isolation by serial di-
lution in 96- well plates. After 7 days culture in a 96- well 
plate, each single cell- derived colony was allowed to grow 
to near confluence and then transferred into individual 
wells of 24- well plates for 3 more days of culture. Upon 
reaching confluence, three quarters of the cells were 
cryopreserved, and one quarter used for DNA extraction. 
PCR and Sanger sequencing were then performed to iden-
tify wild- type (WT), knock- out (KO), and knock- in (KI) 
colonies.
2.6 | Somatic cell nuclear transfer
Sheep SCNT was performed as described by Yang et al. 
for goats20 with the minor alteration that the synthetic 
oviductal fluid (SOF) embryo culture medium was used 
instead of G1. CFTRF508del/F508del and CFTRG542X/G542X fetal 
fibroblast cells were grown to 80%– 90% confluence and 
used as nuclear donor cells for SCNT after 24 h of serum 
starvation (in 0.5% FBS- containing DMEM medium). The 
reconstructed embryos were cultured in SOF medium for 
10– 12 h and then transferred into estrus synchronized re-
cipients as described elsewhere.19,21
2.7 | Identification of CFTRF508del/F508del  
and CFTRG542X/G542X fetuses/lambs
Genomic DNA was extracted from muscle samples col-
lected during the necropsy. Using the set of primers de-
scribed above, PCR and Sanger sequencing analysis were 
used for confirmation of the mutations present in the 
lambs.
2.8 | Off- target analysis
We conducted a BLAST search on the sheep nucleotide 
sequence database with two gRNA sequences as the que-
ries to find the genomic sequences with the highest ho-
mology using Crispor online software (Version 4.97). 
We selected potential off- target sites with the highest se-
quence homology (scores) to each seed sequence. Specific 
PCR primers were designed to amplify DNA fragments of 
approximately 500 bp spanning each OT locus. We used 
PCR and Sanger sequencing for off- target analysis of the 
genomic DNA isolated from cloned CFTRF508del/F508del and 
CFTRG542X/G542X sheep.
2.9 | Histopathologic analysis
Necropsy was performed on all lambs that either died or 
were euthanized within 24 h of birth. The following tissue 
samples were collected and fixed in 10% neutral buffered 
formalin for histology: trachea, lung, thyroid glands, ad-
renal glands, abomasum, intestinal tract, pancreas, liver, 
kidney, urinary bladder, spleen, heart, testis, and vas 
deferens, or the area where the vas deferens is expected. 
Formalin- fixed tissue sections were processed and em-
bedded in paraffin according to the routine histologic 
techniques. Sections, 5- µm thick, were stained with he-
matoxylin and eosin (H&E), based on standard methods, 
and examined by light microscopy.
2.10 | Tracheal cell isolation, primary 
culture, and electrophysiological analysis
G542X and F508del CF STE cells were prepared as in a 
previous study.5 Briefly, tracheal segments were digested 
by injecting the subepithelial space with a collagenase 
solution (type I, 1  mg/mL; Worthington) and incubated 
at 37℃ for 1  h. After digestion, the epithelial sheets on 
the luminal surface were collected by scraping, using a 
plastic coverslip. These sheets were washed and then fur-
ther digested with Accutase into single cells and small 
clumps. The cells were then seeded onto permeable sup-
ports (Costar 3801) with bronchial epithelial growth me-
dium (BEGM; Lonza) in both upper and lower chambers. 
Once the cells were post- confluent for 3  days, the cul-
ture medium was switched to PneumaCult- ALI medium 
(STEMCELL Technologies) in the lower chamber only 
for air– liquid interface (ALI) culture. After 6 weeks, the 
ALI cultures were differentiated into polarized epithelia, 
which were used for the measurements of transepithelial 
electrophysiology. The filter inserts were placed in Ussing 
chambers and bathed on both sides with Krebs- Ringer 
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bicarbonate solution bubbled with 95% O2/5% CO2 
and maintained at 37℃, as described previously.22,23 
Transepithelial voltage was measured and clamped to 0 
to measure the short- circuit current. The epithelium was 
periodically voltage- clamped to non- 0  values to meas-
ure transepithelial resistance. In addition, ciliary beat-
ing was observed and recorded in both STE cultures (see, 
Supporting Information Videos).
2.11 | Effect of CFTR correctors/
potentiator on F508del and G542X CF 
STE cells
F508del STE cell cultures were pretreated with the correc-
tors VX- 809, VX- 661, or VX- 445 at 3.3 μM for 24 h. For the 
triple combination (as in Trikafta®) VX- 661 and VX- 445 at 
3.3 μM were used together for 24 h. At the indicated times, 
amiloride (100 μM, apical), forskolin (10 μM, basolateral), 
VX- 770 potentiator (1  μM, apical & basolateral), gen-
istein (30 μM, apical & basolateral), and CFTR inhibitor 
GlyH- 101 (20 μM, apical) were added for acute treatment. 
G542X CF STE cells were pretreated with the inhibitor of 
NMD SMG1- i (1 μM)18 plus G418 (50 μM) for 24 h with or 
without VX- 661 (3.3 μM), followed by acute treatment as 
described above.
3  |  RESULTS
3.1 | Generation of CFTRF508del/F508del 
and CFTRG542X/G542X sheep fetal fibroblast 
colonies using CRISPR/Cas9 RNP and 
ssODN
Fetal fibroblasts from domestic sheep (O. aries) were used 
in this study, since they are the preferred cell type for clon-
ing.24 The cells were isolated as previously described.21 
We designed specific PCR primers according to the sheep 
CFTR genome sequence (GenBank, NC_019461.2) to 
amplify exon 11 (F: TGAACTCAGCACCCCATCTCTG, 
R: TGCAGGCTTCTTATAGCAGGGG, 624  bp) and 
exon 12 (F: GCTGAGATGTGGTGTTCACA, R: GCATC 
TTCTCTTCCCTGTGC, 560 bp) and parts of the flanking 
intron sequences. We designed guide RNA/Cas9 (gRNA/
Cas9) targeting sites that were close to the F508 and G542 
(gRNA_1: 5’- ATTAAAGATAACATCATCTT- 3’ and 
gRNA_2: 5’- AACATAGTTCTTGGAGAAGG- 3, for exon 
11 and 12, respectively), of the CFTR gene. The F508del 
and G542X mutations were introduced into the corre-
sponding sites of ssODNs in order to induce mutations 
in SFFs via CRISPR- mediated homology- directed repair 
(HDR) (Figure  1A). SFFs were transfected with gRNA/
Cas9 RNP and ssODNs using an electroporation- based 
method. After limiting dilution of the transfected cells, 
we obtained 56 single cell- derived colonies in the F508del 
group and 62 colonies in the G542X group. The PCR and 
Sanger sequencing results demonstrated that mutations, 
including insertions/deletions (indels) mutations and KIs, 
were introduced in 53/56 (94.6%) of colonies targeting the 
F508del site, and four of them (7.1%) contained homozy-
gous F508del mutations (Figure  1B). Whereas a total of 
mutations were found in 61/62 (98.4%) of colonies in the 
G542  site, and nine of them (14.5%) contained homozy-
gous G542X mutations (Figure  1C). Four colonies, two 
from each mutation, were subsequently used for the gen-
eration of CFTRF508del/F508del and CFTRG542X/G542X lambs.
3.2 | Generation of CFTRF508del/F508del and 
CFTRG542X/G542X sheep by SCNT
Four SFFs colonies (two with CFTRF508del/F508del and 
two with CFTRG542X/G542X mutations) were used as 
donor cells for SCNT. In total, 164 cloned embryos were 
transferred into 11 estrus- synchronized recipients. Five 
pregnancies were initially established, two from the 
F508del and three from the G542X cells (Table 1). One 
of the G542X pregnancies was sacrificed around day 40 
of gestation and the fetus was used for SFFsG542X/G542X 
T A B L E  1  Developmental rates following the SCNT using CFTRF508del/F508del and CFTRG542X/G542X fibroblasts as donor cells
KI colonies (Genotype) Targeted exon
No of embryos 
transferred
Pregnancy rate 




Fd78 (F508del/F508del) Exon 11 47 1/3 (33.3) 1/3 (33.3) 1/1 (100)
Fd92 (F508del/F508del) Exon 11 27 1/2 (50.0) 1/2 (50.0) 1/1 (100)
Gx12 (G542X/G542X) Exon 12 48 1/3 (33.3) 0/3 (0)a NA
Gx44 (G542X/G542X) Exon 12 42 2/3 (66.6) 2/3 (66.6) 1/2(50)b 
Total 164 5/11 (45.4) 4/11 (36.3) 3/4 (75)
aFetus collected for isolation of G542X sheep fetus fibroblasts.
bThe second lamb died about 24 h prior to birth.
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cell rederivation. The remaining pregnancies (n  =  4) 
were allowed to go to term. They resulted in three live 
offspring and one stillborn lamb. Abdominal ultrasonog-
raphy confirmed the presence of intestinal obstruction 
(meconium ileus (MI)) in all F508del and G542X CF off-
spring. Thus, they were considered not viable due to the 
MI and were euthanized within a few hours after birth. 
The sequencing results indicated that all cloned fetuses/
lambs carried the same mutations (either F508del or 
G542X) as those of the donor cells they were derived 
from (Figure 1B,C). All lambs were submitted for nec-
ropsy and tissue collection.
8 |   VIOTTI PERISSE et al.
3.3 | Gross and histologic 
characterization of the 
CFTRF508del/F508del and CFTRG542X/G542X sheep
The histopathologic findings of all CFTRF508del/F508del and 
CFTRG542X/G542X sheep are detailed below and summa-
rized in Table 2.
3.3.1 | Intestinal phenotype
Similar to the CFTR- null sheep,5 100% of the 
CFTRF508del/F508del (n  =  2) and CFTRG542X/G542X (n  =  2) 
newborn lambs exhibited intestinal obstruction (MI), 
(Figure  2; Table  2), a phenotype seen only in ~15% of 
human CF babies. An abrupt demarcation between 
F I G U R E  3  Wild- type (A, D, and G), F508del (B, E, and H), and G542X (C, F, and I) newborn lamb pancreas. (A) Normal pancreas 
in a wild- type lamb (arrow). (B) Pancreas in an F508del lamb (arrow). (C) Pancreas in a G542X lamb (arrow). (D) Pancreas of a wild- type 
lamb. (E) Pancreatic acinar atrophy (arrow) and dilatation of acini and ducts (arrowhead) in an F508del lamb. (F) Pancreatic acinar atrophy 
(arrow) and dilatation of acini and ducts (arrowhead) in a G542X lamb. (G) Higher magnification of the pancreas in a wild- type lamb. (H) 
Higher magnification of the pancreatic acinar atrophy and dilatation of acini (arrow) in an F508del lamb. (I) Higher magnification of the 
pancreatic acinar atrophy and dilatation of acini (arrow) and ducts (arrowhead) in a G542X lamb. Hematoxylin and eosin stain (D– I). 40X 
(D– F); bar = 500 μm. 200X (G– I); bar = 100 μm
F I G U R E  2  Wild- type (A, D, G, J, and M), F508del (B, E, H, K, and N), and G542X (C, F, I, L, and O) newborn lamb intestinal tract. 
(A) Normal intestinal tract in a wild- type lamb. Note the even intestinal diameter of the small intestine (arrow) and colon (arrowhead). (B) 
Meconium ileus in an F508del lamb (C) Meconium ileus in a G542X lamb. Note the smaller diameter of the aboral small intestine (arrow), 
and of the colon (arrowhead). (D) Normal small intestine in a wild- type lamb. (E) Small intestine filled with meconium in an F508del 
lamb. (F) Small intestine filled with meconium in a G542X lamb. (G) Higher magnification of the small intestine in a wild- type lamb. 
(H) Higher magnification of the small intestine filled with meconium in an F508del lamb. (I) Higher magnification of the small intestine 
filled with meconium in a G542X lamb. (J) Normal colon in a wild- type lamb. (K) Colon filled with mucus in an F508del lamb. (L) Colon 
filled with mucus in a G542X lamb. (M) Higher magnification of the colon in a wild- type lamb. (N) Higher magnification of the colon in 
an F508del lamb. (O) Higher magnification of the colon in a G542X lamb. Note the large amount of luminal mucus (arrow) and the goblet 
cells distended with mucus (arrowhead). Hematoxylin and eosin stain (D– O). 40X (D– F and J– L); bar = 500 μm. 200X (G– I and M– O); 
bar = 100 μm
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a distended oral intestine and small- diameter aboral 
small intestine and colon (Figure  2B,C) was present in 
three out of four lambs. The change in intestinal diam-
eter at the level of the obstruction was less abrupt and 
extended over an approximately 3  cm long segment in 
one of F508del lamb. Obstruction was consistently seen 
in the mid jejunum. The intestine oral to the obstruction 
point was markedly dilated (ranging from 10 to 40 mm 
in diameter) and contained large amount of meconium 
(Figure  2E,F,H,I). The intestine and colon aboral to 
the obstruction site had a small diameter (4– 8  mm) 
and contained thick mucoid content. Microscopic ex-
amination revealed a mucus filled colonic lumen with 
dilated mucosal glands (Figure  2  K,L,N,O). The gross 
and microscopic lesions were identical to the ones seen 
in CFTR−/− lambs5 and associated with CF disease in 
humans.
3.3.2 | Pancreas
The pancreas of all animals was grossly normal in size 
(Figure  3B,C). However, in all CF lambs, microscopic 
examination showed variably sized areas of atrophic exo-
crine pancreas admixed with normal pancreatic tissue 
(Figure 3E). The atrophic exocrine pancreatic tissue was 
composed of small acini with sometimes a dilated lumen 
separated by increased amount of stroma arising from ei-
ther collapsing of the preexisting stroma or mild fibrosis 
(Figure  3E,F,H,I). Several acini or ducts with a dilated 
lumen contained few neutrophils and macrophages. In 
addition, a few acini and/or ducts had a markedly dilated 
lumen that contained lightly basophilic flocculent mate-
rial that stained with alcian blue and periodic acid- Schiff 
stain supporting it is likely mucus. These early pancreatic 
lesions are similar to those reported in humans with CF 
F I G U R E  4  Wild- type (A, D, and G), F508del (B, E, and H), and G542X (C, F, and I) newborn lamb liver. (A) Normal liver wild- type 
lamb. Note the well- developed gallbladder. (B) Gallbladder hypoplasia in an F508del lamb. (C) Gallbladder hypoplasia in a G542X lamb. 
Note the small gallbladder (arrow). (D) Normal liver in a wild- type lamb. (E) Biliary fibrosis in an F508del lamb. (F) Biliary fibrosis in a 
G542X lamb. (G) Higher magnification of the liver in a wild- type lamb. (H) Higher magnification of the liver with biliary fibrosis in an 
F508del lamb. (I) Higher magnification of the liver with biliary fibrosis in a G542X lamb. Note the intrahepatic cholestasis (arrow) in 
image H and I. Hematoxylin and eosin stain (D– I). 40X (D– F); bar = 500 μm. 200X (G– I); bar = 100 μm
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disease25 and were also seen in a few CFTR−/− lambs as 
described by.5
3.3.3 | Liver and gallbladder
The liver of all lambs was grossly normal but the gall-
bladder in three out of four lambs was approximately one 
quarter of the expected size (Figure  4B,C). In the lamb 
with a gallbladder of normal size, the cystic duct was 
tortuous and the gallbladder was found approximately 
2  cm more ventral than normal. Microscopic examina-
tion revealed moderate to severe bile duct proliferation 
(ductular reaction) and mild fibrosis in most portal tracts 
diffusely (biliary fibrosis) in three out of four animals 
(Figure 4E,F,H,I). Similar lesions but mild were present 
in the stillborn lamb. Intrahepatic cholestasis was severe 
in three lambs, and mild in one lamb (Figure 4H,I). These 
liver lesions were also seen in CFTR−/− sheep5 and are 
similar to the phenotype of early onset CF liver disease 
reported in humans.26,27
3.3.4 | Epididymis and vas deferens
None of the lambs had a grossly visible or microscopically 
detectable vas deferens. Epididymis was present in all 
animals. However, bilateral cryptorchidism, was present 
in both F508del CF lambs, and unilateral cryptorchidism 
was present in the G542X CF lambs (one right and one 
left cryptorchid). Cryptorchidism, an absence of at least 
one testis from the scrotum, is not a CF- associated le-
sion and was not previously described in our CFTR- null 
sheep,5 also it may occur due to various factors, such as 
birth weight, absence of appendix testis, as well as mater-
nal and environmental factors that disrupt hormones and 
physical changes.28
3.3.5 | Lungs
The lungs of the F508del and G542X CF lambs were 
grossly and microscopically unremarkable.
3.3.6 | Kidney
Hydronephrosis, a common pathology in cloned sheep29,30 
and cattle31,32 associated with SCNT, was evident in all 
four CF lambs.
3.3.7 | Other organs
One lamb (G542X CF) had a moderately rounded heart 
due to right ventricular dilation, whereas all other ani-
mals had no heart lesions. Three lambs had a small (± 
20  mL) to moderate (± 100  mL) amount of translucent 
watery fluid in the abdominal cavity, while the stillborn 
lamb had the thoracic and abdominal cavities filled with 
dark red watery fluid. These lesions were most likely asso-
ciated with SCNT.33 No microscopic lesions were detected 
in the other evaluated tissues including thyroid gland, ad-
renal glands, trachea, thymus, spleen, umbilicus, skeletal 
muscle, forestomach, urinary bladder, and brain obtained 
from either F508del or G542X CF lambs.
3.4 | Functional 
rescue of mutant ovCFTR using 
hCFTR therapeutic compounds
In order to evaluate whether the Vertex compounds, which 
achieve partial functional rescue of mutations in human 
CFTR (hCFTR), are also effective on equivalent mutations 
in ovine CFTR (ovCFTR), we treated STE cells with the 
relevant reagents and monitored CFTR channel activity 
in Ussing chambers. Treatment with VX- 661,13 VX- 809,14 
and VX- 445,15 all three of which promote maturation/cor-
rect folding of F508del hCFTR, increased the function of 
F508del ovCFTR in STE cells (Figure 5A). Following ac-
tivation of F508del ovCFTR with the VX- 770 potentiator 
of hCFTR,16 the increased short- circuit current caused by 
the corrector was VX- 445 > VX- 661 > VX- 809 (Figure 5A). 
The most potent activation was observed with the triple 
combination of simultaneous treatment with VX- 445 and 
VX- 661, followed by VX- 770 (Figure S1). In the G542X 
STE cells, the function of ovCFTR G542X was moderately 
restored by SMG1- i18 and G41817 treatments (Figure 5B). 
Furthermore, exposure to G418 with VX- 661 alone did not 
improve the CFTR function (not shown).
3.5 | Evaluation of potential 
introduction of mutations in off- target 
sites by CRISPR/Cas9
To examine whether unintended off- targeting (OT) events 
occurred in CFTRF508del/F508del or CFTRG542X/G542X sheep, we 
conducted a blast search of the sheep nucleotide sequence 
database with CFTR targeting sequences as the queries to 
find the genomic sequences with the highest homologies. 
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We chose 10 potential OT sites related to the gRNA_1 and 
11 OT sites to the gRNA_2 in the sheep genome with the 
highest sequence homology (scores >1) for the OT analy-
sis (Table S1). Specific PCR primers were designed to am-
plify DNA fragments ranging from 300 to 800 bp spanning 
each potential OT locus (Table S2). Genomic DNA isolated 
from two F508del and three G542X cloned sheep were 
used as the templates for PCR amplification. Sequencing 
results verified that none of the animals had mutations in 
the analyzed potential OT sites (Figure S2).
4  |  DISCUSSION
One impediment to advancing the understanding of CF dis-
ease mechanisms is the limited ability of most CF animal 
models to recapitulate some aspects of humans’ disease 
phenotype (reviewed in34). Also, the CFTR- null models 
do not represent the same molecular mechanisms seen in 
patients with the most common mutations, F508del and 
G542X, as the random disruption of the gene may lead 
to unpredictable effects on protein synthesis. Currently, 
a few F508del and G542X CF animal models have been 
established, including pig,35 rat,36,37 and mouse38 for the 
F508del mutation, and mouse39 and rat40 for the G542X 
mutation. The F508del mutants have similar abnormali-
ties as seen in their respective CFTR- null models of the 
same species, except with less severe damage in some or-
gans due to residual CFTR function35,36 (reviewed in41). 
The availability of sheep models of the F508del and G542X 
mutations provides an extremely valuable resource, not 
only to reveal critical events in the early pathology of CF 
disease, which are not accessible in humans, but also to 
evaluate new therapeutic approaches. Similar to our ob-
servations on the efficacy of the Vertex therapeutics to 
restore the function of ovine F508del CFTR protein, pri-
mary nasal cultures of F508del rats demonstrated that the 
combination of VX- 809 and VX- 770, human therapeutics, 
restored CFTR function, and improved the Cl− anion 
transport up to 37%.36 Thus these therapeutics may be ef-
fective in multiple species as the molecular mechanism of 
the CFTR synthesis seems to be similar. Of note, ongo-
ing efforts to optimize CFTR correctors, which although 
they correct the folding process do not restore the reduced 
open state probability of the F508del CFTR channel,42 may 
also benefit from additional animal model systems for in 
vivo studies. Nonetheless, even with these most promis-
ing postnatal treatments, they cannot fully correct all the 
deficits arising from the absence of appropriate CFTR lev-
els during fetal development. For this reason, the F508del 
CF sheep models may also be an excellent candidate to 
test not only postnatal but also prenatal therapeutic ap-
proaches. Sheep, like humans, frequently have one to two 
offspring, which provides an advantage for prenatal treat-
ment. CF pig models, on the other hand, require a mini-
mum of four offsprings to maintain the pregnancy,43 and 
normally have 6– 10 offspring per pregnancy.
G542X CF mice and rats were generated recently39,40 
and exhibit a similar phenotype to their CFTR- null 
F I G U R E  5  Representative traces of short- circuit current in 
CFTR F508del and G542X sheep tracheal epithelial cell cultures. 
Primary cultures of sheep tracheal epithelial cells were seeded onto 
permeable filter supports and maintained at the ALI for 6 weeks. 
At the time of measurement, the filter inserts were placed in Ussing 
chambers and bathed on both sides with Krebs- Ringer bicarbonate 
solution bubbled with 95% O2/5% CO2 and maintained at 37℃. 
(A) Effect of CFTR correctors on F508del cells. Cultures were 
pretreated with VX- 809, VX- 661, or VX- 445 at 3.3 μM for 24 h. At 
the indicated times, amiloride (Amil, 100 μM, apical), forskolin 
(For, 10 μM, basolateral), VX- 770 (1 μM, apical & basolateral), 
genistein (Gen, 30 μM, apical & basolateral), and GlyH- 101 (20 μM, 
apical) were added for acute treatment. (B) Effect of G418 and 
SMG1- i on G542 cells. Cells were pretreated with SMG1- i (1 μM) 
plus G418 (50 μM) for 24 h with or without VX- 661 (3.3 μM), 
followed by acute treatment as described above
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models with no residual CFTR functionality. However, or-
ganoids isolated from the intestine of G542X CF mice and 
epithelial cells isolated from the trachea of G542X CF rats 
indicated that CFTR protein synthesis could be rescued 
by G418 antibiotic treatment, thus, partially restoring the 
CFTR channel. Also, McHugh et al. observed that the in-
testinal organoids from the same G542X CF mouse, when 
treated with PTC124, showed no enhancement of CFTR 
gene transcription.39 More recently, McHugh et al. tested 
the efficacy of a combination of read- through agents and 
NMD inhibitors to restore the CFTR function in primary 
airway epithelial (PAE) cells from a G542X CF mouse 
model. Their analysis strongly indicates that the SMG1- i 
and G418 act in synergy to restore the CFTR channel in 
PAE cell cultures.44 Furthermore, several studies45– 48 have 
demonstrated that drugs like G418 and PTC124 enable ri-
bosomes to read through nonsense mutation sites of PTC 
by inserting a near- cognate aminoacyl tRNA that inserts a 
range of alternative amino acids to allow translation of the 
full- length protein; thus, preventing early PTC. However, 
these compounds cause side effects or provide no signifi-
cant enhancement, that is, gentamicin is nephro and oto-
toxic, whereas PTC124 has little impact on clinical disease 
in CF patients in Phase 3  clinical trials. Therefore, cur-
rently, there are no adequate and safe therapies available 
to recover the production of the CFTR gene for nonsense 
mutations.12,39 Again, the G542X sheep model may serve 
as not only an excellent candidate for the discovery of new 
corrective drugs but also prenatal therapeutic approaches.
Among all etiologies associated with CF, one of par-
ticular importance is the early lung pathology, which is 
likely triggered by functional inactivation of the CFTR 
protein early in life. Current models of human lung devel-
opment heavily rely on seminal work in the sheep lung, 
carried out many decades ago (reviewed in49).50 Also, the 
developmental time course of CFTR gene expression in 
the sheep lung appears similar to limited observations in 
humans.51– 54 Hence, it is evident that the availability of 
CF sheep models could be a valuable asset to reveal key 
events in the human CF lung, which are not accessible for 
study in vivo in humans.55 Similar to human CF patients, 
newborn CF sheep do not exhibit any histological lung 
lesions. However, further molecular characterization of 
the lung tissue derived from these animals could provide 
novel insights into CF- associated deficits occurring prior 
to observations of clinical lesions. Due to meconium ileus, 
our current models only survive 24– 48 h after birth, and 
therefore, the short life span prevents further studies. To 
overcome this limitation, we intend to genetically correct 
the intestinal phenotype by expressing a transgene under 
regulation of an intestinal cell- specific promoter, similarly 
to what was previously accomplished in mice, ferrets, and 
pigs.56– 58 On these aspects, CF sheep models carrying the 
most common mutations (F508del and G542X) seem nec-
essary in order to advance the research on the CF disease.
Here, we generated two models of human CF muta-
tions in sheep that develop pathologies similar to what 
is seen in human patients. Analogous to the F508del CF 
rat and G542X CF rat and mouse, our F508del and G542X 
CF sheep cells are very responsive to the CFTR correc-
tors (VX- 661, VX- 809, and VX- 445) and potentiator (VX- 
770) in F508del STE cells, as well as for SMG1- i and G418 
with and without corrector (VX- 661) in G542X STE cells, 
respectively. As was shown earlier, the ovCFTR channel 
is more active than the human channel and the F508del 
mutation in sheep has a reduced impact in vitro on chan-
nel gating when compared to hCFTR protein.59 Thus, our 
F508del CF sheep model may contribute substantially to 
the discovery of new therapeutics. G542X CF models, on 
the other hand, remain poorly understood as only one 
mouse model has recently been generated, and does not 
recapitulate all aspects of CF in humans as reviewed in.39 
Our G542X CF model will likely provide a robust platform 
to study in- depth the effects of nonsense mutations in the 
CFTR gene and provide an opportunity to enhance the in 
vivo development of therapeutics that overcome the PTC. 
Moreover, with the rapid advancement of CRISPR/Cas9 
technologies as molecular tools, both CF models may 
provide excellent platforms to observe the correction of 
the CFTR gene through gene editing and gene therapy 
approaches.
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